

News release

Kyowa Kirin to Launch HARUROPI® TAPE for Parkinson's Disease in Japan

TOKYO, December 16th, 2019 --- Kyowa Kirin Co., Ltd. (Tokyo Japan; President and CEO: Masashi Miyamoto, "Kyowa Kirin") announced that HARUROPI® TAPE will be launched in Japan on December 17th, 2019.

HARUROPI® TAPE is a systemic transdermal Parkinson's disease treatment patch developed by Hisamitsu Pharmaceutical Co., Inc. (Tosu city, Saga, Japan; President and CEO: Kazuhide Nakatomi, "Hisamitsu Pharmaceutical") utilizing its TDDS (Transdermal Drug Delivery System) technologies. The product was listed on the National Health Insurance (NHI) Drug Price List on November 19th, 2019 followed the manufacturing and marketing approval in Japan on September 20th, 2019.

Under the terms of the agreement signed with Hisamitsu Pharmaceutical in February 2019, Kyowa Kirin is responsible for commercializing HARUROPI® TAPE in Japan. Hisamitsu Pharmaceutical and Kyowa Kirin expect to contribute to a higher quality of life of patients with Parkinson's disease by providing proper medical information of the product. In addition, Kyowa Kirin will make milestone payments to Hisamitsu Pharmaceutical based on the amount of sales.

Hisamitsu Pharmaceutical and Kyowa Kirin expect the product to be a new option for treating Parkinson's disease owing to its long-lasting effect by maintaining stable blood drug concentration.

The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.

<Summary of the HARUROPI® TAPE>

| | |
|--------------|---|
| Product Name | HARUROPI® TAPE 8 mg HARUROPI® TAPE 16 mg HARUROPI® TAPE 24 mg |
|--------------|---|

| | | |
|---------------------------|--|--|
| | HARUROPI® TAPE 32 mg HARUROPI® TAPE 40 mg | |
| Generic Name | Ropinirole hydrochloride | |
| Indication | Parkinson's disease | |
| Dosage and Administration | Usually, for adults initially apply 8 mg formulation as Ropinirole hydrochloride once daily, observing the progress, increased as needed the daily dose by 8 mg at intervals of 1 week or more. For any dose, apply once daily to the skin of the chest, abdomen, flank, thigh or upper arm and replace every 24 hours. Further, the dosage can be adjusted according to the age and the symptoms, the daily dosage should not exceed 64 mg as Ropinirole hydrochloride. | |
| Size of the Formulation | HARUROPI® TAPE 8 mg 5.33 cm ² HARUROPI® TAPE 16 mg 10.67 cm ² HARUROPI® TAPE 24 mg 16.00 cm ² HARUROPI® TAPE 32 mg 21.33 cm ² HARUROPI® TAPE 40 mg 26.67 cm ² | |
| Date of approval | September 20 th , 2019 | |
| Date of NHI price listing | November 19 th , 2019 | |
| NHI drug price | HARUROPI® TAPE 8 mg 404.90 yen/ 1 sheet HARUROPI® TAPE 16 mg 623.00 yen/ 1 sheet HARUROPI® TAPE 24 mg 801.50 yen/ 1 sheet HARUROPI® TAPE 32 mg 958.40 yen/ 1 sheet HARUROPI® TAPE 40 mg 1,101.00 yen/ 1 sheet | |

About Parkinson's Disease

Parkinson's disease is a progressive, neurodegenerative disease characterized by motor symptoms such as tremors, rigidity, bradykinesia and postural instability. It is thought to be caused by progressive degeneration associated with decreased levels of dopamine in certain parts of the brain, i.e., the substantia nigra and striatum.